Endothelial cell alloantigens.

J. Cerilli,L. Brasile

IF: 1.014

1980-09-01

Transplantation Proceedings

Abstract:

What problem does this paper attempt to address?

Editorial comments (B): extracellular cyclic nucleotides.

A. Broadus

Abstract:
ICD Leads Extraction and Clearing of Access Way in a Patient With Superior Vena Cava Syndrome: Building A Tunnel

Márcio Galindo Kiuchi,Ricardo Luiz Lima Andrade,Gustavo Ramalho da Silva,Hanry Barros Souto,Shaojie Chen,Humberto Villacorta Junior

DOI: https://doi.org/10.1097/MD.0000000000001481

Abstract:Central vein disease is defined as at least 50% narrowing up to total occlusion of central veins of the thorax including superior vena cava, brachiocephalic, subclavian, and internal jugular vein. Thrombosis due to intravascular leads occurs in approximately 30% to 45% of patients early or late after implantation of a pacemaker by transvenous access.In this case, we report a male patient, 65-years old, hypertensive, type 2 diabetic, with atherosclerotic disease, coronary artery disease, underwent coronary artery bypass surgery in the past 10 years, having already experienced an acute myocardial infarction, bearer automatic implantable cardioverter defibrillator for 8 years after an episode of aborted sudden death due to ischemic cardiomyopathy, presenting left superior vena cava syndrome. The use of clopidogrel and rivaroxaban for over a year had no benefit on symptoms improvement.After atrial and ventricular leads extraction, a new shock lead was positioned in the right ventricle using active fixation and a new atrial lead was positioned in the right atrium, passing inside of the stents. Two days after the procedure the patient was asymptomatic and was discharged.
Managing Implanted Cardiac Electronic Devices in Patients With Severe Tricuspid Regurgitation: JACC State-of-the-Art Review

Rebecca T Hahn,Bruce Larry Wilkoff,Susheel Kodali,Ulrika Maria Birgersdotter-Green,Gorav Ailawadi,Karima Addetia,Martin Andreas,Angelo Auricchio,Frederick Ehlert,Isaac George,Aakriti Gupta,Rachel Harrison,Edwin C Ho,Fred Kusumoto,Azeem Latib,Patrick O'Gara,Kristen K Patton,Sean Pinney,Emily P Zeitler,Michael J Mack,Martin B Leon,Laurence M Epstein,Heart Valve Collaboratory and Heart Rhythm Society

DOI: https://doi.org/10.1016/j.jacc.2024.02.045

2024-05-21

Abstract:Orthotopic transcatheter tricuspid valve replacement (TTVR) devices have been shown to be highly effective in reducing tricuspid regurgitation (TR), and interest in this therapy is growing with the recent commercial approval of the first orthotopic TTVR. Recent TTVR studies report preexisting cardiac implantable electronic device (CIED) transvalvular leads in ∼35% of patients, with entrapment during valve implantation. Concerns have been raised regarding the safety of entrapping leads and counterbalanced against the risks of transvenous lead extraction (TLE) when indicated. This Heart Valve Collaboratory consensus document attempts to define the patient population with CIED lead-associated or lead-induced TR, describe the risks of lead entrapment during TTVR, delineate the risks and benefits of TLE in this setting, and develop a management algorithm for patients considered for TTVR. An electrophysiologist experienced in CIED management should be part of the multidisciplinary heart team and involved in shared decision making.
281 CARDIAC RESYNCHRONIZATION TERHAPY IN PERSISTENT LEFT SUPERIOR VENA CAVA WITH A BRIDGING INNOMINATE VEIN

Mattia Liccardo,Giovanni Pilato,Domenico Vittoria,Maria Rea,Carmine Ciardiello,Ersilia Cipolletta

DOI: https://doi.org/10.1093/eurheartjsupp/suac121.051

2022-12-14

European Heart Journal Supplements

Abstract:Abstract Background The Persistent Left (PL) Superior Vena Cava (SVC) is a congenital malformation of the thoracic venous return that has an incidence of 0.2-3% in the general population and an incidence of about 0.5% in patients undergoing cardiac implantable electronic device. In this case, the placement of the leads, especially for the Right Ventricle (RV) and Left Ventricle (LV) through one of the branches could be challenging. Methods A 66-year-old man with hypertension, diabetes and dyslipidemia, in optimal pharmacologic therapy for congestive heart failure (NYHA II), hospitalized for recurrent syncopal episodes, with extreme sinus bradycardia, first-degree AV block and Left Bundle Branch Block, The patient had a LV hypertrophy and mild global systolic function (LV ejection fraction of 40%) for these we opted for a pacemaker CRT device implantation. Results Isolation of left cephalic vein was used as venous access for right atrium (RA) and RV leads while Seldinger technique via subclavian vein was used as venous access for LV lead. The guidewire through the subclavian vein pointed out the presence of PLSVC. Left subclavian venogram confirmed PLSVC and revealed a bridging innominate vein. To pass through the innominate vein and reach the SVC, a 0.035-inch hydrophilic guidewire was used. A 6Fr-sheath was advanced through the hydrophilic guidewire, subsequently a second metallic guidewire was advanced through the same introducer by removing the dilator. The RV and RA leads were placed respectively on low right interventricular septum and RA appendage passing through bridging innominate vein. Electrical parameters were normal. For the placement of the LV lead a 9.5Fr sheath introducer was advanced over the guidewire through the PLSVC. A venogram showed a lateral and a postero-lateral branch of the coronary sinus with acute angulation. With a 6Fr quadripolar Josephson catheter the postero-lateral branch was entered, eventually a 9Fr peelable outer guide catheter was advanced through the electrophysiology catheter becoming selective with the interested branch. A quadripolar S shaped lead was used, it was advanced into the targeted vein through a 0,014fr hydrophilic guidewire. Adequate electrical parameters and stability were achieved. Conclusion Lead implantation in patient with PLSVC is challenging. Placing the RA and RV leads through SVC ensure a better stability along time. The cannulation of CS is easily achieved by approach via PLSVC while selective vein cannulation can be difficult due to the modified acute angulation.

cardiac & cardiovascular systems
Observational Study of Trans-Septal Endocardial Left Ventricle Lead Implant for Effective Cardiac Resynchronization Therapy in Patients with Heart Failure and Challenging Coronary Sinus Anatomy

Arsalan Farhangee,Mark J. Davies,Katie Gaughan,Mihai Mesina,Ion Mîndrilă

DOI: https://doi.org/10.3390/biomedicines12122693

IF: 4.757

2024-11-28

Biomedicines

Abstract:Background: When conventional trans-venous CS lead placement fails, trans-septal endocardial left ventricle lead placement is an alternative technique used to capture the left ventricle endocardially; however, its use is limited due to a lack of evidence, practice uptake, and clinical trials. Methods: In this single-center cohort study, we evaluated the efficiency of the procedure, post-procedural complication rate, rate of thromboembolic events, overall survival rate, and changes in the echocardiographic parameters, brain natriuretic peptide (BNP) level, and New York Heart Association (NYHA) class, both before and after TSLV lead implantation. Results: The TSLV lead implant is safe and improves EF, LVEDV, LVESV, and LVIDd. It significantly reduces the NTproBNP levels and the NYHA class; however, the rate of stroke incidence remains high, at 9%. Conclusions: We demonstrated a high success rate of trans-septal left ventricular endocardial lead implantation, LV reverse remodeling was noted, and patients had a favorable clinical response; however, there was an increased risk of systemic embolization after the trans-septal LV lead implant.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Safety and Effectiveness of Abre Self-Expanding Venous Stent for Treatment of Superior Vena Cava Syndrome

Thomas J. An,Stephanie L. McNamara,Ali Ardestani,Omar Zurkiya,Alexis Cahalane,Michael S. Stecker,Yan Epelboym,Ezra Burch,Khanant Desai,Sanjeeva P. Kalva

DOI: https://doi.org/10.1177/15385744241251638

IF: 0.9

2024-04-28

Vascular and Endovascular Surgery

Abstract:Vascular and Endovascular Surgery, Ahead of Print. PurposeSuperior vena cava (SVC) syndrome is a constellation of symptoms that results from partial or complete SVC obstruction. Endovascular SVC stenting is an effective treatment for SVC syndrome with rapid clinical efficacy and low risk of complications. In this study, we assess the technical and clinical outcomes of a cohort of patients with SVC syndrome treated with the AbreTM self-expanding venous stent (Medtronic, Inc, Minneapolis, MN, USA).MethodsAn institutional database was used to retrospectively identify patients with SVC syndrome treated with AbreTM venous self-expanding stent placement between 2021-2023. Patient demographic data, technical outcomes, treatment effectiveness, and adverse events were obtained from the electronic medical record. Nineteen patients (mean age 58.6) were included in the study. Thirteen interventions were performed for malignant compression of the SVC, 5 for central venous catheter-related SVC stenosis, and 1 for HD fistula-related SVC stenosis refractory to angioplasty.ResultsPrimary patency was achieved in 93% of patients (17/19). Two patients (7%) required re-intervention with thrombolysis and angioplasty within 30 days post-stenting. Mean duration of clinical and imaging follow-up were 228.7 ± 52.7 and 258.7 ± 62.1 days, respectively. All patients with clinical follow-up experienced significant improvement in clinical symptoms post-intervention. No stent related complications were identified post-intervention.ConclusionsTreatment of SVC syndrome with the AbreTM self-expanding venous stent has high rates of technical and clinical success. No complications related to stent placement were identified in this study.

surgery,peripheral vascular disease
Unintended Sequalae of Long-Term Transvenous Pacemaker Leads in a Patient With Congenital Heart Disease

Soyoung Cheon,Muhammad Faateh,Awais Ashfaq

DOI: https://doi.org/10.1177/21501351241269856

Abstract:Long-term use of transvenous pacemakers, a common modality used for symptomatic bradyarrhythmias, can lead to rare but significant complications, especially in patients with congenital heart disease. We present a complex and challenging surgical lead extraction for a patient with long-standing superior vena cava syndrome resulting from prolonged transvenous leads.
Safety and efficacy of combined dilation/stenting of venous abnormalities, including complete obstructions, during lead extractions in patients with congenital heart disease

William P. Knapp,Edward T. O'Leary,Brian Quinn,Diego Porras,Douglas Y. Mah

DOI: https://doi.org/10.1111/jce.16202

IF: 2.7

2024-02-10

Journal of Cardiovascular Electrophysiology

Abstract:Introduction Management of transvenous leads in patients with congenital heart disease (CHD) can be complicated by venous obstructions and residual shunts. We present our experience performing concurrent lead extraction and dilation/stenting of venous pathways, including patients with complete venous obstruction. Methods All cases of concurrent lead extraction and recanalization of vena cavae/baffles between 2017 and 2021 at Boston Children's Hospital were retrospectively included and reviewed for safety and efficacy. Results Eight patients, 4 female, median 38.5 years of age (range 16.7−49 years) and 81.6 kg weight (range 41.3−97.8 kg) at time of procedure were included. All patients had CHD, a majority (n = 7) having transposition of the great arteries palliated via atrial switch. All leads were removed in their entirety, with most patients having two leads extracted (n = 7). Median lead dwell time was 13.8 years (range 3.6−35.3 years). Three patients had complete obstructions, three required stenting of their innominate veins and three required recanalization of their femoral vessels. Median procedure time was 9.8 h (range 5.4−12.8 h). Complications included blood transfusion (n = 2), arrhythmia (n = 3), pleural effusion (n = 1), and pressure ulcer (n = 1). There were no cardiac perforations, venous tears, or deaths. Conclusion Lead extraction along with dilation and stenting of venous anomalies, though long in duration, proved effective with minimal complications. This combined procedure can safely and effectively resolve complete obstructions secondary to transvenous leads.

cardiac & cardiovascular systems
Unveiling a Unique Presentation of Superior Vena Cava Syndrome Succeeding a Traumatic Motor Vehicle Crash and Implantable Cardioverter-Defibrillator Lead Placement

Jenna Sapone,Mathai Chalunkal

DOI: https://doi.org/10.7759/cureus.61303

2024-05-29

Cureus

Abstract:Superior vena cava (SVC) syndrome, once a rarity, has seen an uptick in cases with diverse origins. While this disease process is clinically diagnosable, imaging modalities and tissue biopsies further refine interventions. The clinical presentation includes but is not limited to edema of the arms, neck, and head, facial plethora, cyanosis, and or distention of subcutaneous vessels. SVC syndrome can be attributed to extrinsic compression or thrombosis in many cases. If symptoms are not life-threatening, the overall morbidity is based on the underlying root cause. Few cases have been reported with associated death due to epistaxis. However, the obstruction itself can be initially asymptomatic and then slowly progress over months to years. This case report highlights a distinct instance of SVC syndrome with notable risk factors: implantable cardioverter defibrillator placement and prior cardiac trauma status post-intervention.
Trans-septal left ventricular endocardial lead in a patient with extensive anterior myocardial infarction and left ventricle (LV) apical endoventriculoplasty using a Vascutek patch-case report

Arsalan Farhangee,Edward Davies,Guy Haywood,Katie Gaughan,Ion Mindrila

DOI: https://doi.org/10.21037/acr-23-109

2024-09-13

Abstract:Background: Cardiac resynchronization therapy (CRT) implantation has significantly improved quality of life and reduced overall mortality due to heart failure. The conventional method of CRT implantation is implanting a left ventricle (LV) lead into a side branch of the coronary sinus (CS) tributary to pace the epicardial surface and capture the LV. This is safe, and well tolerated with a high success rate. The rate of failure to place an LV lead has decreased over time, however, there are still challenging cases where a conventional CRT implant fails and alternative techniques are being considered, one such technique is trans-septal endocardial LV lead placement used to capture the LV, endocardially but its use is limited due to lack of evidence, practice uptake and clinical trials. Case description: We present, a case report of a patient for whom we successfully used a trans-septal left ventricle (TSLV) endocardial lead implantation approach following a failed LV lead implant via the CS to get effective cardiac resynchronisation. Conclusions: Post-TSLV lead implantation follow-up checks were normal with good electrical parameters and appropriate biventricular pacing. No post-procedural complications were reported, and echocardiographic parameters improved at follow-up. We believe, although, TSLV lead implant is more complex and often double operators are required, in selected patients, it can be a safe alternative following a failed traditional LV lead implant via the CS.
Hospital-based emergency contraception.

B. Wagner

DOI: https://doi.org/10.1093/AJHP/61.17.1771

2004-09-01

American Journal of Health-System Pharmacy

Abstract:
Transvenous Cardiac Implantable Electronic Device Implantation in Patients with Persistent Left Superior Vena Cava in a Tertiary Center

Xueying Chen,Ziqing Yu,Jin Bai,Wei Wang,Shengmei Qin,Jingfeng Wang,Zhe Sun,Fei Han,Yangang Su,Junbo Ge

DOI: https://doi.org/10.1007/s10840-018-0377-4

IF: 24

2017-01-01

Journal of the American College of Cardiology

Abstract:Purpose Persistent left superior vena cava (PLSVC) is rare and often asymptomatic, which might cause difficulties in the implantation of cardiac implantable electronic devices (CIEDs). The aim of this study was to determine the prevalence of PLSVC and to study the clinical characteristics and significance of PLSVC in patients with CIED implantation. Methods Thirty-three patients with PLSVC were collected from 7047 CIED recipients over recent 10 years in our center. These 33 patients were divided into three groups: PLSVC in the absence of RSVC, with a pacemaker implantation (group A, n = 7); double superior vena cava (DSVC), having both PLSVC and RSVC, with a pacemaker or implantable cardioverter defibrillator (ICD) implantation (group B, n = 20); DSVC with a cardiac resynchronization therapy/cardiac resynchronization therapy defibrillator (CRT/CRT-D) implantation (group C, n = 6). The clinical characteristics, pacing parameters, and complications were collected and compared among three groups. Results The prevalence of PLSVC in our patients implanting CIEDs in the recent 10 years was 0.47%. Coronary sinus diameter, right atrium lead type (active or passive), right atrium lead location (right atrium appendage or lateral wall), right ventricle lead location (right ventricular apex or right ventricular outflow tract), and procedure duration were found to be significantly different among three groups, while the incidence of complications and pacing parameters was not significantly different among three groups during long-term follow-up. Conclusions Although the presence of PLSVC made the CIED implantation more challenging and might increase the complications related to the procedure, the pacing parameters were not likely to be affected during long-term follow-up.
Novel atrioventricular sequential pacing approach using a transvenous atrial pacemaker and a leadless pacemaker: a case report

Elhosseyn Guella,Frances Devereux,Fozia Zahir Ahmed,Peter Scott,Colin Cunnington,Amir Zaidi

DOI: https://doi.org/10.1093/ehjcr/ytab219

2021-07-01

Abstract:Abstract Background The use of transvenous pacing leads is associated with the risk of developing tricuspid valve (TV) dysfunction. This develops through several mechanisms including the failure of leaflet coaptation or direct damage to the TV or to its sub-valvular apparatus and can result in significant tricuspid regurgitation (TR). Multiple approaches to pacemaker implantation after transvenous lead extraction (TLE) or surgical TV repair have been described. Placement of pacing leads across the TV is generally avoided in such circumstances. Case summary A 66-year-old woman presented with a year-long history of exertional dyspnoea, peripheral oedema, and postural neck pulsations. Her medical history included a dual-chamber pacemaker implantation for sinus node dysfunction 14 years ago. Echocardiography revealed severe lead-related TR. Her case was discussed in our multi-disciplinary team meeting. A decision was made to perform a TLE and implant a leadless pacemaker in an attempt to avoid open-heart surgery if possible. This was reserved as an option in the event of persistent severe TR. Transvenous extraction of the right ventricular lead was performed. The atrial lead was preserved and connected to and AAI device. A Micra AV was implanted allowing for atrioventricular (AV) synchronous pacing. Discussion We present the first case of successful implementation of AV sequential pacing using a dual-pacemaker approach involving the use of an AAI pacemaker and a Micra AV device. This was performed after TLE for severe lead-related TR.
Percutaneous Balloon Venoplasty for Symptomatic Lead Related Venous Stenosis

Carli J. Peters,Weeranun D. Bode,David S. Frankel,Fermin Garcia,Gregory E. Supple,Jay S. Giri,Ramanan Kumareswaran,Sanjay Dixit,David J. Callans,Francis E. Marchlinski,Robert D. Schaller

DOI: https://doi.org/10.1016/j.hrthm.2024.10.010

IF: 6.779

2024-10-12

Heart Rhythm

Abstract:Background Lead-related venous stenosis (LRVS) is common after transvenous lead implantation and generally diagnosed incidentally. Symptomatic LRVS, causing discomfort and swelling, is less common. Objective To report on the management and outcomes of patients with symptomatic LRVS after percutaneous balloon venoplasty Methods We included patients with symptomatic LRVS unresponsive to >30 days of anticoagulation who underwent venoplasty at the Hospital of the University of Pennsylvania between 2014 and 2020. Transvenous lead extraction (TLE) was performed first if the lesion could not be crossed with a wire. Results Eighteen patients (mean 62±10 years, 44% female) underwent 27 venoplasty procedures. Symptoms included arm swelling in 9 (50%), facial/neck swelling in 1 (6%), and both in 8 (44%). Venography revealed LRVS in the axillary/subclavian veins in 10 (56%), the brachiocephalic vein in 6 (33%), and the superior vena cava in 4 (11%). Most patients (83%) required TLE prior to venoplasty and only 5/18 (28%) remained with leads crossing the stenosed segment. Thirteen patients (72%) had complete symptom resolution, four (22%) had partial resolution due to secondary lymphedema, and one showed no improvement. Patients with complete resolution had shorter times from symptom onset to intervention (195 versus 690 days, p=0.02). Conclusion LRVS can affect any part of the venous system and may present with swelling of the arm, face/neck, or both. Balloon venoplasty is safe and effective, often requires TLE, and is particularly durable when leads no longer cross the stenosed region. Venoplasty is less effective for secondary lymphedema, highlighting the need for timely intervention.

cardiac & cardiovascular systems
Moving Dipole Inverse ECG and EEG Solutions

R. Gulrajani,F. Roberge,P. Savard

DOI: https://doi.org/10.1109/TBME.1984.325257

IF: 4.6

1984-12-01

IEEE Transactions on Biomedical Engineering

Abstract:This paper reviews and updates the single moving dipole (SMD) and two moving dipole (TMD) inverse electrocardiographic and electroencephalographic solutions. These inverse solutions are particularly appropriate when the electrical activity of the heart or brain may be represented by one or two well-localized foci. They attempt to match the measured body surface or evoked scalp potentials to potentials generated on the surface of a model of the intervening volume conductor by one or two moving current dipoles, respectively. The two alternative methods of solution are discussed initially. The first is a direct least-squares error match of measured and model-generated surface potentials, the second an indirect solution based on the least-squares error match of the potentials due to equivalent multipole series representations of the real and model sources, respectively. Next, brief reviews of moving dipole inverse solutions in the EEG and ECG fields are presented. Simulation studies, as well as experimental and clinical studies in animals and humans, are described. The Discussion section summarizes the optimum solution approaches that should be used in clinical EEG and ECG studies in man. It also cautions against the temptation to translate the numerical adequacy of inverse SMD and TMD solutions into physiological validity, without independent knowledge as to the nature of the underlying sources.
Pacemaker lead thrombosis - a rare cause of breathlessness

Megan Ashleigh Kelly,Alexander Davidson,Kirsty Griffiths,Renzo Pessotto,Stephen James Leslie

DOI: https://doi.org/10.22551/2024.43.1102.10288

2024-06-24

Abstract:As the number of pacemaker insertions increases to manage numerous cardiac arrhythmias, the number of complications is also increasing as a result. More common complications such as infection and lead displacement are routinely discussed with patients before they undergo the procedure. However rare complications such as superior vena cava syndrome are not discussed during the consenting period. But they do occur, as seen in this case of a 69-year-old male. This fit and active man had a right-sided dual-chamber pacemaker inserted due to sinus node disease and presented 5 years later with symptoms suggestive of superior vena cava obstruction (SVCO). Despite anticoagulation and before surgical intervention could be performed, the patient developed a right-sided chylothorax which was drained. An autologous pericardial patch repair of the SVC and a thrombectomy of SVC clots was subsequently performed. This was only partially successful and the SVCO recurred. A low fatty chain diet was initiated to manage the chylothorax, which remains stable. This rare complication has left the patient with a small pleural effusion and chronic pleural thickening. They can still exercise with mild breathlessness. The management of such a complication, which requires the input of many specialists, is challenging and often does not completely resolve all symptoms. For this reason, superior vena cava obstruction should be considered as a risk during the consenting procedure for a pacemaker insertion.
Vascular access challenges in hemodialysis patients with superior vena cava syndrome

Rosalinda D'Amico,Andrew Nicoli,Andrei Zdoroveac,Lorenz Gürke,Andrej Isaak

DOI: https://doi.org/10.1177/11297298241227549

2024-02-07

The Journal of Vascular Access

Abstract:The Journal of Vascular Access, Ahead of Print. Background:Superior vena cava syndrome in hemodialysis patients resulting from previous or current use of a tunneled central vein catheter is a rare but potentially severe condition. Two aspects have to be addressed during management and treatment: the restoration of central venous flow and the creation of an alternative vascular access to guarantee hemodialysis.Research design:Conforming to the current guidelines and literature, we present a stepwise approach and discuss therapeutic options. The removal of the tunneled central vein catheter should be attempted and a native vascular access created whenever feasible.Results:First, an upper extremity AVF should be preserved or, as in our case, made functional. Endovascular treatment of CVSO should primarily consist of balloon dilatation. Placement of a stent or stent graft should be considered as a secondary option. HeRO graft placement may be considered in recurrent CVSO and recanalization with a Surfacer. LL-AVF or AVG need to be discussed and may be an alternative for certain HD patients when the risk of lower limb ischemia and infection is considered.Conclusion:Several therapeutic options are available and the basic principles are well established in the literature, although the level of evidence is not high. Therefore, we propose a stepwise and interdisciplinary approach to guide the challenging decision-making process in SVC.

peripheral vascular disease
Surgical removal of an atrial septal occluder device embolized to the main pulmonary artery.

E. Boysan,O. Çiçek,M. Çiçek,Ziyaddin Hamurcu,Sami Gurkahraman

DOI: https://doi.org/10.14503/THIJ-12-3003

2014-02-04

Texas Heart Institute Journal

Abstract:Percutaneous closure of atrial septal defects in adults has emerged as an alternative to surgery. We report a sequela of such closure in a 16-year-old boy: embolization of the atrial septal defect occluder into the main pulmonary artery when the patient experienced an episode of intense coughing immediately after device deployment. We removed the device surgically and closed the atrial septal defect in a standard manner, with an autologous pericardial patch.
Prevalence and management of electrical lead abnormalities in cardiac implantable electronic device leads

Hilary Roberts,Kara Matheson,John Sapp,Martin Gardner,Chris Gray,Amir AbdelWahab,David Lee,Ciorsti MacIntyre,Ratika Parkash

DOI: https://doi.org/10.1016/j.hroo.2023.05.002

2023-05-20

Heart Rhythm O2

Abstract:Background: Electrical lead abnormalities (ELAs) can result in device malfunction, leading to significant morbidity in patients with cardiac implantable electronic devices (CIEDs). Objective: We sought to determine the prevalence and management of ELAs in patients with CIEDs. Methods: This was a retrospective cohort study of patients implanted with a CIED between 2012 and 2019 at a tertiary care center. The primary outcome was ELA defined as increased capture threshold (≥2× implantation value), decreased sensing (≤0.5 implantation value), change in impedance (>50% over 3 months), or nonphysiologic potentials. A secondary outcome of device clinic utilization was also collected. Results: There were 2996 unique patients (35% female) included with 4600 leads (57% Abbott, 43% Medtronic). ELAs were observed in 135 (3%) leads, including 124 (92%) Abbott and 10 (7%) Medtronic leads (hazard ratio 9.25, P < .001). Mean follow-up was 4.5 ± 2.2 years. ELAs were associated smaller lead French size, atrial location, and Abbott leads. Lead revision was required in 28% of cases. Patients with lead abnormalities had 38% more in-clinic visits per patient year of follow-up compared with those without (P < .001). Conclusion: ELAs were more frequent in certain models, which increased rates of revision and follow-up. Identification of factors that mitigate these abnormalities to improve lead performance are required to improve care for these devices and provide efficient healthcare.
Abstract 8803: Bioprosthetic Tricuspid Valve Regurgitation Associated with Device Lead Implantation

Mackram F Eleid,Lori A Blauwet,Yong-Mei Cha,Heidi M Connolly,Peter A Brady,Joseph A Dearani,Raúl E Espinosa

DOI: https://doi.org/10.1161/circ.124.suppl_21.a8803

IF: 37.8

2011-11-22

Circulation

Abstract:Background Little is known about the effects of permanent transvenous device leads on bioprosthetic tricuspid valve (BTV) function. Hypothesis The goal of this study was to test the hypothesis that transvalvular device leads promote clinically significant BTV regurgitation. Methods A retrospective review of 58 patients who underwent BTV implantation and subsequently required endocardial pacemaker (n=52) or defibrillator (n=6) lead implantation through the BTV was conducted. Patient and prosthesis characteristics, lead type, and clinical events were collected. The incidence and severity of prosthetic tricuspid regurgitation (TR), determined by Doppler echocardiography, was compared to 265 patients who underwent BTV implantation without undergoing subsequent transvalvular device lead implantation. Results Over a mean follow up of 25 months, 5 patients (9%) with a transvalvular lead developed ≥ moderate prosthetic TR compared to 12 patients (5%) in the control group (P = 0.20). Kaplan Meier survival analysis revealed no significant difference in the incidence of TR in BTV patients with and without transvalvular leads (p = 0.45). Clinically significant prosthetic TR in patients with and without a transvalvular lead more commonly occurred 2 years or later after lead implantation or BTV implantation (4/5, 80% and 10/12, 83%). Conclusions Compared to BTV controls, there was no significant difference in the incidence of ≥ moderate prosthetic TR in patients with a transvalvular pacemaker or defibrillator lead (p = 0.45). Transvalvular lead implantation appears to be an acceptable approach for patients with a BTV who require permanent pacemaker or defibrillator placement.

cardiac & cardiovascular systems,peripheral vascular disease

Endothelial cell alloantigens.

Editorial comments (B): extracellular cyclic nucleotides.

ICD Leads Extraction and Clearing of Access Way in a Patient With Superior Vena Cava Syndrome: Building A Tunnel

Managing Implanted Cardiac Electronic Devices in Patients With Severe Tricuspid Regurgitation: JACC State-of-the-Art Review

281 CARDIAC RESYNCHRONIZATION TERHAPY IN PERSISTENT LEFT SUPERIOR VENA CAVA WITH A BRIDGING INNOMINATE VEIN

Observational Study of Trans-Septal Endocardial Left Ventricle Lead Implant for Effective Cardiac Resynchronization Therapy in Patients with Heart Failure and Challenging Coronary Sinus Anatomy

Safety and Effectiveness of Abre Self-Expanding Venous Stent for Treatment of Superior Vena Cava Syndrome

Unintended Sequalae of Long-Term Transvenous Pacemaker Leads in a Patient With Congenital Heart Disease

Safety and efficacy of combined dilation/stenting of venous abnormalities, including complete obstructions, during lead extractions in patients with congenital heart disease

Unveiling a Unique Presentation of Superior Vena Cava Syndrome Succeeding a Traumatic Motor Vehicle Crash and Implantable Cardioverter-Defibrillator Lead Placement

Trans-septal left ventricular endocardial lead in a patient with extensive anterior myocardial infarction and left ventricle (LV) apical endoventriculoplasty using a Vascutek patch-case report

Hospital-based emergency contraception.

Transvenous Cardiac Implantable Electronic Device Implantation in Patients with Persistent Left Superior Vena Cava in a Tertiary Center

Novel atrioventricular sequential pacing approach using a transvenous atrial pacemaker and a leadless pacemaker: a case report

Percutaneous Balloon Venoplasty for Symptomatic Lead Related Venous Stenosis

Moving Dipole Inverse ECG and EEG Solutions

Pacemaker lead thrombosis - a rare cause of breathlessness

Vascular access challenges in hemodialysis patients with superior vena cava syndrome

Surgical removal of an atrial septal occluder device embolized to the main pulmonary artery.

Prevalence and management of electrical lead abnormalities in cardiac implantable electronic device leads

Abstract 8803: Bioprosthetic Tricuspid Valve Regurgitation Associated with Device Lead Implantation